Related references
Note: Only part of the references are listed.CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2012)
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults
Adriana Olar et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2012)
Frequent BRAF Gain in Low-Grade Diffuse Gliomas with 1p/19q Loss
Young-Ho Kim et al.
BRAIN PATHOLOGY (2012)
KIAA1549-BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults
Manuela Badiali et al.
BRAIN PATHOLOGY (2012)
Molecular pathogenesis of IDH mutations in gliomas
Koichi Ichimura
BRAIN TUMOR PATHOLOGY (2012)
IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival
Niklas Thon et al.
CANCER (2012)
Studying a Complex Tumor Potential and Pitfalls
Siyuan Zheng et al.
CANCER JOURNAL (2012)
Prognostic value of Ki67 index in anaplastic oligodendroglial tumours - a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Matthias Preusser et al.
HISTOPATHOLOGY (2012)
Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials
Guanghui Gao et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Detection of oncometabolite 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma
Juliya Kalinina et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Recent advances in the molecular understanding of glioblastoma
Fonnet E. Bleeker et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas
Rezvan Ahmadi et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth
Catherine Goze et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas
Tareq A. Juratli et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
Marta Mellai et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
BRAF Alterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549:BRAF Fusion Variants
Alex Lin et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers
Stephen Yip et al.
JOURNAL OF PATHOLOGY (2012)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology
David Capper et al.
ACTA NEUROPATHOLOGICA (2011)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
Genevieve Schindler et al.
ACTA NEUROPATHOLOGICA (2011)
Genetic profile of astrocytic and oligodendroglial gliomas
Hiroko Ohgaki et al.
BRAIN TUMOR PATHOLOGY (2011)
IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group
Ian F. Pollack et al.
CHILDS NERVOUS SYSTEM (2011)
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
Christian Hartmann et al.
CLINICAL CANCER RESEARCH (2011)
BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma
Cynthia Hawkins et al.
CLINICAL CANCER RESEARCH (2011)
A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2011)
Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas
Karine Jacob et al.
CLINICAL CANCER RESEARCH (2011)
BRAF Activation Induces Transformation and Then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model
Eric H. Raabe et al.
CLINICAL CANCER RESEARCH (2011)
Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study
Andreas H. Habberstad et al.
DIAGNOSTIC PATHOLOGY (2011)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
Joerg Felsberg et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
PHASE II EVALUATION OF GEFITINIB IN PATIENTS WITH NEWLY DIAGNOSED GRADE 4 ASTROCYTOMA: MAYO/NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0074
Joon H. Uhm et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis
Robert A. Olson et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2011)
BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults
M. Hasselblatt et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2011)
BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
Dora Dias-Santagata et al.
PLOS ONE (2011)
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Chetan Bettegowda et al.
SCIENCE (2011)
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing
Joerg Felsberg et al.
ACTA NEUROPATHOLOGICA (2010)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas
Craig Horbinski et al.
ACTA NEUROPATHOLOGICA (2010)
Temozolomide (Temodar)
J. R. Wesolowski et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2010)
Molecular Classification of Low-Grade Diffuse Gliomas
Young Ho Kim et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2010)
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Nicolas Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature
Georgia Levidou et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
Michael Jansen et al.
LANCET NEUROLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
O-6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Alba A. Brandes et al.
NEURO-ONCOLOGY (2010)
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
C. Houillier et al.
NEUROLOGY (2010)
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
M. Labussiere et al.
NEUROLOGY (2010)
The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas
Lee A. D. Cooper et al.
PLOS ONE (2010)
Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma
Andrey Korshunov et al.
ACTA NEUROPATHOLOGICA (2009)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours
K. Jacob et al.
BRITISH JOURNAL OF CANCER (2009)
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
Yukihiko Sonoda et al.
CANCER SCIENCE (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Mi Ran Kang et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues
Craig Horbinski et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Koichi Ichimura et al.
NEURO-ONCOLOGY (2009)
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
H. J. Dubbink et al.
NEUROLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Gliomas With 1p/19q Codeletion: a.k.a. Oligodendroglioma
Gregory Cairncross et al.
CANCER JOURNAL (2008)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Can morphology predict 1p/19q loss in oligodendroglial tumours?
D. Scheie et al.
HISTOPATHOLOGY (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
Francois Ducray et al.
MOLECULAR CANCER (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents
Bernd Kaina et al.
DNA REPAIR (2007)
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations
Judith Jeuken et al.
ACTA NEUROPATHOLOGICA (2007)
Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome
Johan M. Kros et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2007)
Temozolomide for low-grade gliomas - Predictive impact of 1p/19q loss on response and outcome
G. Kaloshi et al.
NEUROLOGY (2007)
Genetic pathways to primary and secondary glioblastoma
Hiroko Ohgaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
New insight into BRAF mutations in cancer
Nathalie Dhomen et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
MGMT methylation:: A marker of response to temozolomide in low-grade gliomas
Sibille Everhard et al.
ANNALS OF NEUROLOGY (2006)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Robert B. Jenkins et al.
CANCER RESEARCH (2006)
Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss
Constance A. Griffin et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
C. Walker et al.
NEUROLOGY (2006)
Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas
H Colman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Changing paradigms - An update on the multidisciplinary management of malignant glioma
Roger Stupp et al.
ONCOLOGIST (2006)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms
NH Tran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization grade II astrocytoma or oligoastrocytoma -: A long-term analysis
M Ständer et al.
CANCER (2004)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
The ErbB receptors and their role in cancer progression
T Holbro et al.
EXPERIMENTAL CELL RESEARCH (2003)
Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology
G Reifenberger et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons
CJ Lee et al.
MOLECULAR BRAIN RESEARCH (2002)
Share Paper
